A study evaluating of PEGPH20 for pancreatic cancer: Precision Promise pragramm
Phase of Trial: Phase IV
Latest Information Update: 09 Jan 2017
At a glance
- Drugs Hyaluronidase (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 09 Jan 2017 According to a Halozyme Therapeutics media release, this trial will be led by the Pancreatic Cancer Action Network.
- 17 Oct 2016 New trial record
- 04 Oct 2016 According to a Halozyme Therapeutics media release, Precision Promise plans to enroll patients at 12 initial consortium sites in Spring 2017. A companion diagnostic assay will be used for assessment of hyaluronan in this trial.